• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alumis Inc.

    5/18/26 4:28:13 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    DEFA14A 1 tm266546d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     

    Washington, D.C. 20549 

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 

     

    Filed by the Registrant x 
     
    Filed by a party other than the Registrant  ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    x Definitive Additional Materials

     

    ¨ Soliciting Material under § 240.14a-12

     

    Alumis Inc.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required

     

    ¨ Fee paid previously with preliminary materials

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! ALUMIS INC. 2026 Annual Meeting Vote by June 29, 2026 11:59 PM ET You invested in ALUMIS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 30, 2026. Vote Virtually at the Meeting* June 30, 2026 9:00 A.M. (PACIFIC TIME) Virtually at: www.virtualshareholdermeeting.com/ALMS2026 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V86686-P48503 Get informed before you vote View the Notice and Proxy Statement and our Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 16, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. ALUMIS INC. 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V86687-P48503 1. To elect the three Class II director nominees named below to serve until the Company’s 2029 annual meeting of stockholders. For Nominees: 01) James B. Tananbaum, M.D. 02) Lynn Tetrault, J.D. 03) Zhengbin (Bing) Yao, Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for the Company’s fiscal year ending December 31, 2026. For

    Get the next $ALMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    5/15/2026$25.00Buy → Neutral
    H.C. Wainwright
    3/11/2026$46.00Strong Buy
    Raymond James
    2/25/2026$44.00Buy
    Stifel
    1/21/2026$37.00Buy
    Chardan Capital Markets
    7/25/2025$17.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alumis downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Alumis from Buy to Neutral and set a new price target of $25.00

    5/15/26 8:25:19 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Alumis with a new price target

    Raymond James initiated coverage of Alumis with a rating of Strong Buy and set a new price target of $46.00

    3/11/26 8:36:17 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Alumis with a new price target

    Stifel initiated coverage of Alumis with a rating of Buy and set a new price target of $44.00

    2/25/26 7:48:26 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

    – Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms – – Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) – – Data continue to underscore envudeucitinib's potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track – – Potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – SOUT

    5/14/26 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

    Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib's early onset and broad clinical benefitEnvudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 programResults presented as a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual MeetingConference call and webcast scheduled for March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT SOUTH SAN

    3/28/26 1:30:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

    – Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma com

    3/19/26 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $9,999,995 worth of shares (588,235 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/13/26 6:20:06 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Labs, Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:59:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Capital Management Vi Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:58:40 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Alumis Inc.

    DEFA14A - ALUMIS INC. (0001847367) (Filer)

    5/18/26 4:28:13 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Alumis Inc.

    DEF 14A - ALUMIS INC. (0001847367) (Filer)

    5/18/26 4:27:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alumis Inc.

    10-Q - ALUMIS INC. (0001847367) (Filer)

    5/14/26 4:16:40 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Drappa Jorn exercised 26,852 shares at a strike of $6.65, increasing direct ownership by 83% to 59,339 units (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    5/27/26 7:06:45 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Foresite Labs, Llc

    4 - ALUMIS INC. (0001847367) (Issuer)

    4/3/26 3:55:39 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Foresite Capital Management Vi Llc

    4 - ALUMIS INC. (0001847367) (Issuer)

    4/3/26 3:54:50 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Financials

    Live finance-specific insights

    View All

    Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

    Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib's early onset and broad clinical benefitEnvudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 programResults presented as a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual MeetingConference call and webcast scheduled for March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT SOUTH SAN

    3/28/26 1:30:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

    – Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe pl

    3/18/26 8:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

    – Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

    1/6/26 7:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    8/27/24 4:20:38 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alumis Inc.

    SC 13G - ALUMIS INC. (0001847367) (Subject)

    7/11/24 4:30:21 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    7/5/24 9:30:17 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care